BIOTRON LIMITED — Investor Presentation 2014

Jan 13, 2014

==> picture [227 x 35] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au

14 January 2014

The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000

(2 pages by email)

Dear Madam

BIOTRON LIMITED TO PRESENT AT BIOTECH SHOWCASE™ 2014

Biotron Limited advises that Dr Michelle Miller, Managing Director, will be presenting at the Biotech Showcase™ 2014 Conference being held this week in San Francisco, California, USA.

In addition, Dr Miller will give briefings to US institutional investors and pharmaceutical company representatives as part of activities surrounding the annual JP Morgan Healthcare Conference. This is one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco.

The Biotech Showcase features corporate presentations by innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. Now in its sixth year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

The presentation by Dr Miller will highlight the Company's recent advances, including:

• Commencement of a pivotal 3-month dosing, phase 2 trial of BIT225 in Hepatitis C virus (HCV) genotype 1 and 3 patients.

• 100% response at three months of HIV/HCV genotype 3 co-infected patients with one month dosing of BIT225 in combination with interferon and ribavirin.

• 100% response at 48 weeks of HCV genotype 1 patients with one month dosing of BIT225 in combination with interferon and ribavirin.

• Demonstration that BIT225 can target and reduce levels of HIV hiding in reservoirs in HIVinfected patients.

A copy of the presentation can be found on Biotron’s website at www.biotron.com.au.

About Biotron

Biotron Limited is engaged in the research, development and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.

Enquiries

Dr Michelle Miller Managing Director Biotron Limited +61-2 9805 0488 +61-(0)412313329

Rudi Michelson Monsoon Communications +61-3 9620 3333

Yours sincerely

==> picture [95 x 60] intentionally omitted <==

Peter J. Nightingale Company Secretary

pjn7598

2